Parasiticidal effect of δ-aminolevulinic acid-based photodynamic therapy for cutaneous leishmaniasis is indirect and mediated through the killing of the host cells

Experimental Dermatology

Volumn 16, Issue 8, 2007, Pages 651-660

  Akilov, Oleg E ^a   Kosaka, Sachiko ^a   O'riordan, Katie ^a   Hasan, Tayyaba ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Aminolevulinic acid; Cutaneous leishmaniasis; Leishmania major; Photodynamic therapy

Indexed keywords

AMINOLEVULINIC ACID; INTERLEUKIN 6; PROTOPORPHYRIN;

AMASTIGOTE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BAGG ALBINO MOUSE; CONTROLLED STUDY; DRUG MECHANISM; FEMALE; IN VITRO STUDY; IN VIVO STUDY; LEISHMANIA MAJOR; MACROPHAGE; MOUSE; NONHUMAN; PHOTODYNAMIC THERAPY; SKIN LEISHMANIASIS;

AMINOLEVULINIC ACID; ANIMALS; CELL LINE, TRANSFORMED; DISEASE MODELS, ANIMAL; EAR, EXTERNAL; INTERLEUKIN-6; LEISHMANIA MAJOR; LEISHMANIASIS, CUTANEOUS; MACROPHAGES; MICE; MICE, INBRED BALB C; MONOCYTES; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; PROTOPORPHYRINS;

EID: 34447503490     PISSN: 09066705     EISSN: 16000625     Source Type: Journal    
DOI: 10.1111/j.1600-0625.2007.00578.x     Document Type: Article

References (35)

1. Hamblin M R, Hasan T. Photodynamic therapy: A new antimicrobial approach to infectious disease? Photochem Photobiol Sci 2004: 3: 436-450.
2. Huang Z. A review of progress in clinical photodynamic therapy. Technol Cancer Res Treat 2005: 4: 283-293.
3. Jori G, Brown S B. Photosensitized inactivation of microorganisms. Photochem Photobiol Sci 2004: 3: 403-405.
4. Gardlo K, Hanneken S, Ruzicka T, Neumann N J. Photodynamic therapy of cutaneous leishmaniasis. A promising new therapeutic modality. Hautarzt 2004: 55: 381-383.
5. Gardlo K, Horska Z, Enk C D et al. Treatment of cutaneous leishmaniasis by photodynamic therapy. J Am Acad Dermatol 2003: 48: 893-896.
6. Enk C D, Fritsch C, Jonas F et al. Treatment of cutaneous leishmaniasis with photodynamic therapy. Arch Dermatol 2003: 139: 432-434.
7. Asilian A, Davami M. Comparison between the efficacy of photodynamic therapy and topical paromomycin in the treatment of Old World cutaneous leishmaniasis: A placebo-controlled, randomized clinical trial. Clin Exp Dermatol 2006: 31: 634-637.
8. Sohl S, Kauer F, Paasch U, Simon J C. Photodynamic treatment of cutaneous leishmaniasis. J Dtsch Dermatol Ges 2007: 5: 128-130.
9. WHO. Weekly Epidemiological Record. Geneva: WHO, 2002: 1.
10. Murray H W, Berman J D, Davies C R, Saravia N G. Advances in leishmaniasis. Lancet 2005: 366: 1561-1577.
11. Wortmann G, Miller R S, Oster C, Jackson J, Aronson N. A randomized, double-blind study of the efficacy of a 10- or 20-day course of sodium stibogluconate for treatment of cutaneous leishmaniasis in United States military personnel. Clin Infect Dis 2002: 35: 261-267.
12. Rimington C. Haem biosynthesis and porphyrias: 50years in retrospect. J Clin Chem Clin Biochem 1989: 27: 473-486.
13. Kennedy J C, Pottier R H. Endogenous protoporphyrin IX, a clinically useful photosensitizer for photodynamic therapy. J Photochem Photobiol B 1992: 14: 275-292.
14. Sah J F, Ito H, Kolli B K, Peterson D A, Sassa S, Chang K P. Genetic rescue of Leishmania deficiency in porphyrin biosynthesis creates mutants suitable for analysis of cellular events in uroporphyria and for photodynamic therapy. J Biol Chem 2002: 277: 14902-14909.
15. Chang C S, Chang K P. Heme requirement and acquisition by extracellular and intracellular stages of Leishmania mexicana amazonensis. Mol Biochem Parasitol 1985: 16: 267-276.
16. Steiger R F, Steiger E. A defined medium for cultivating Leishmania donovani and L. braziliensis. J Parasitol 1976: 62: 1010-1011.
17. Spath G F, Beverley S M. A lipophosphoglycan-independent method for isolation of infective Leishmania metacyclic promastigotes by density gradient centrifugation. Exp Parasitol 2001: 99: 97-103.
18. Ortel B, Chen N, Brissette J, Dotto G P, Maytin E, Hasan T. Differentiation-specific increase in ALA-induced protoporphyrin IX accumulation in primary mouse keratinocytes. Br J Cancer 1998: 77: 1744-1751.
19. Taleb-Contini S H, Salvador M J, Balanco J M, Albuquerque S, de Oliveira D C. Antiprotozoal effect of crude extracts and flavonoids isolated from Chromolaena hirsuta (asteraceae). Phytother Res 2004: 18: 250-254.
20. Moreira M E, Del Portillo H A, Milder R V, Balanco J M, Barcinski M A. Heat shock induction of apoptosis in promastigotes of the unicellular organism Leishmania (Leishmania) amazonensis. J Cell Physiol 1996: 167: 305-313.
21. Kiderlen A F, Kaye P M. A modified colorimetric assay of macrophage activation for intracellular cytotoxicity against Leishmania parasites. J Immunol Methods 1990: 127: 11-18.
22. Belkaid Y, Kamhawi S, Modi G et al. Development of a natural model of cutaneous leishmaniasis: Powerful effects of vector saliva and saliva preexposure on the long-term outcome of Leishmania major infection in the mouse ear dermis. J Exp Med 1998: 188: 1941-1953.
23. Dutta S, Ray D, Kolli B K, Chang K P. Photodynamic sensitization of Leishmania amazonensis in both extracellular and intracellular stages with aluminum phthalocyanine chloride for photolysis in vitro. Antimicrob Agents Chemother 2005: 49: 4474-4484.
24. Schuster F L, Sullivan J J. Cultivation of clinically significant hemoflagellates. Clin Microbiol Rev 2002: 15: 374-389.
25. Luksiene Z. Photodynamic therapy: Mechanism of action and ways to improve the efficiency of treatment. Medicina (Kaunas) 2003: 39: 1137-1150.
26. Evans S, Matthews W, Perry R, Fraker D, Norton J, Pass H I. Effect of photodynamic therapy on tumor necrosis factor production by murine macrophages. J Natl Cancer Inst 1990: 82: 34-39.
27. Gollnick S O, Evans S S, Baumann H et al. Role of cytokines in photodynamic therapy-induced local and systemic inflammation. Br J Cancer 2003: 88: 1772-1779.
28. Yamamoto N, Homma S, Sery T W, Donoso L A, Hoober J K. Photodynamic immunopotentiation: In vitro activation of macrophages by treatment of mouse peritoneal cells with haematoporphyrin derivative and light. Eur J Cancer 1991: 27: 467-471.
29. von Stebut E. Cutaneous Leishmania infection: Progress in pathogenesis research and experimental therapy. Exp Dermatol 2007: 16: 340-346.
30. Akilov O E, Kosaka S, O'Riordan K et al. The role of photosensitizer molecular charge and structure on the efficacy of photodynamic therapy against leishmania parasites. Chem Biol 2006: 13: 839-847.
31. Malik Z, Ehrenberg B, Faraggi A. Inactivation of erythrocytic, lymphocytic and myelocytic leukemic cells by photoexcitation of endogenous porphyrins. J Photochem Photobiol B 1989: 4: 195-205.
32. Rittenhouse-Diakun K, Van Leengoed H, Morgan J et al. The role of transferrin receptor (CD71) in photodynamic therapy of activated and malignant lymphocytes using the heme precursor delta-aminolevulinic acid (ALA). Photochem Photobiol 1995: 61: 523-528.
33. Li G, Szewczuk M R, Pottier R H, Kennedy J C. Effect of mammalian cell differentiation on response to exogenous 5-aminolevulinic acid. Photochem Photobiol 1999: 69: 231-235.
34. Ortel B, Sharlin D, O'Donnell D, Sinha A K, Maytin E V, Hasan T. Differentiation enhances aminolevulinic acid-dependent photodynamic treatment of LNCaP prostate cancer cells. Br J Cancer 2002: 87: 1321-1327.
35. Kosaka S, Kawana S, Zouboulis C C, Hasan T, Ortel B. Targeting of sebocytes by aminolevulinic acid-dependent photosensitization. Photochem Photobiol 2005: 82: 453-457.